Follow us on or join ours

The small capital company Agenus Inc. intends to raise $ 50 million to $ 100 million by issuing digital assets backed by planned sales of an experimental anti-cancer drug. This is a completely innovative approach when it comes to the biotechnology industry.

Agenus and innovative biotechnology security tokens

As the company promises, digital assets will enable investment in the future sale of individual products, while exerting limited influence on shareholders. The company intends to offer its innovative, biotechnology security tokens (referred to by the company as BESTs) with a value of at least 25 million dollars. General manager of the company, Garo Armen, he argues that thanks to this type of innovative solutions, it is possible to submit a presentation much more focused on a specific product.

American company Agenus concentrating on immuno-oncological treatment, and is currently conducting clinical trials of the drug for cervical cancer, which can be approved already in the 2021 year. The digital offer, however, carries a certain degree of risk. First, to start generating income, the drug must be approved by securities regulators. Although the company's representatives ensure that the offer complies with the regulations of the Securities and Exchange Commission of the United States (SEC), it has not been finally approved by the Commission. This, according to Armen, takes place within a few months.

According to experts, the offer will help accelerate the development of an anti-cancer drug, although it may prove slightly dilutive for the shareholders themselves. At the same time, the management of Agenus ensures that the BESTs offer has nothing to do with cryptocurrencies, and the company does not currently participate in the cryptography market. Moreover, the company plans to take appropriate measures to protect investors if the drug is not allowed to circulate.

tokens companies are based on technology blockchain enabling verification and registration of transactions. Agenus acquires funds through a digital investment group Atomic Capital. Group representatives say that more and more biotechnology companies are turning towards digital financial methods.

4.7 / 5 - (4 votes)

Tokeny.pl is a cryptocurrency site run by a crypto team of enthusiasts. The main area of ​​our interest are cryptocurrencies, tokens, personal tokens as well as blockchain technology. On the pages of our website we will present independent cryptocurrency reviews and interesting articles from the market. In addition, we present the current rates of all critics. The site also has a multi-functional cryptocurrency calculator as well as traditional currencies.

The information posted on the Tokeny.pl portal is for informational purposes only and does not constitute investment advice or financial recommendation within the meaning of the law, including the Regulation of the Minister of Finance of 19 October 2005. The published content does not constitute an investment offer.

Tokeny.pl is not responsible for decisions made based on the information provided. Investments in cryptocurrencies, OTC instruments and CFDs involve the risk of losing some or all of the invested capital. Profits on such markets are dependent on market volatility and the financial leverage mechanism used, which can lead to losses exceeding the value of the initial deposit. Therefore, such investments may be inappropriate for people who do not have the appropriate experience or risk tolerance.

Copyright © 2018 - 2024 Tokeny.pl

My Newsletter

Sign Up For Updates & Newsletters

© 2025 Your Company. All rights reserved.